Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 3056847, 2 pages

Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders

1Department of Pharmacy, University of Malakand, Khyber Pakhtunkhwa, Pakistan
2Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan
3School of Medicine, Indiana University, Bloomington, IN, USA
4Department of Pharmacy, University of Swabi, Khyber Pakhtunkhwa, Pakistan
5Department of Pharmacy, Abdul Wali Khan University, Mardan, Khyber Pakhtunkhwa, Pakistan

Correspondence should be addressed to Nasiara Karim; moc.liamtoh@mirak.araisan

Received 4 March 2018; Accepted 4 March 2018; Published 3 April 2018

Copyright © 2018 Nasiara Karim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Kessler, S. Aguilar-Gaxiola, J. Alonso et al., “The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys,” Epidemiologia e Psichiatria Sociale, vol. 18, no. 1, pp. 23–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Paul, D. Adeloye, R. George-Carey, I. Kolčić, L. Grant, and K. Y. Chan, “An estimate of the prevalence of epilepsy in Sub–Saharan Africa: A systematic analysis,” Journal of Global Health, vol. 2, no. 2, article 020405, 2012. View at Publisher · View at Google Scholar
  3. S. S. Clevenger, D. Malhotra, J. Dang, B. Vanle, and W. W. IsHak, “The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder,” Therapeutic Advances in Psychopharmacology, vol. 8, no. 1, pp. 49–58, 2017. View at Publisher · View at Google Scholar
  4. H. A. Whiteford, A. J. Ferrari, L. Degenhardt, V. Feigin, and T. Vos, “The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010,” PLoS ONE, vol. 10, no. 2, Article ID e0116820, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Nasri, A. Baradaran, H. Shirzad, and M. Rafieian-Kopaei, “New concepts in nutraceuticals as alternative for pharmaceuticals,” International Journal of Preventive Medicine, vol. 5, no. 12, pp. 1487–1499, 2014. View at Google Scholar · View at Scopus
  6. H. Pathan and J. Williams, “Basic opioid pharmacology: an update,” British Journal of Pain, vol. 6, no. 1, pp. 11–16, 2012. View at Publisher · View at Google Scholar
  7. J. Olin and L. Schneider, “Galantamine for Alzheimer's disease,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD001747, 2002. View at Google Scholar · View at Scopus
  8. M. B. Colovic, D. Z. Krstic, T. D. Lazarevic-Pasti, A. M. Bondzic, and V. M. Vasic, “Acetylcholinesterase inhibitors: pharmacology and toxicology,” Current Neuropharmacology, vol. 11, no. 3, pp. 315–335, 2013. View at Google Scholar
  9. M.-C. Boll, M. Alcaraz-Zubeldia, and C. Rios, “Medical management of parkinson's disease: focus on neuroprotection,” Current Neuropharmacology, vol. 9, no. 2, pp. 350–359, 2011. View at Publisher · View at Google Scholar · View at Scopus